You are here

  • Home
  • Archive
  • Volume 67, Issue 3
  • Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response

Citation Tools

Article menu

Download PDFPDF

Extended report
Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Braun J, Baraliakos X, Listing J, et al
Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response
Annals of the Rheumatic Diseases 2008;67:340-345.